Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: A report from the childhood cancer survivor study

Clinical Cancer Research

Volumn 20, Issue 4, 2014, Pages 904-911

  Gramatges, Maria M ^a   Liu, Qi ^c   Yasui, Yutaka ^c   Okcu, M Fatih ^a   Neglia, Joseph P ^d   Strong, Louise C ^b   Armstrong, Gregory T ^e   Robison, Leslie L ^e   Bhatia, Smita ^f  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF MINNESOTA   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; EPIPODOPHYLLOTOXIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BONE TUMOR; BRAIN TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVOR; CARCINOGENESIS; CASE CONTROL STUDY; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DNA CONTENT; DRUG EXPOSURE; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC PARAMETERS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LEUKEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION FIELD; RETROSPECTIVE STUDY; SARCOMA; SECOND CANCER; SINGLE COPY GENE RATIO; SOFT TISSUE SARCOMA; TELOMERE; TELOMERE HOMEOSTASIS; THYROID CANCER; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CHILD; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SURVIVORS; TELOMERE; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84896735329     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2076     Document Type: Article

References (50)

1. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368-79.
2. Jenkinson HC, Hawkins MM, Stiller CA, Winter DL, Marsden HB, Stevens MC. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer 2004;91: 1905-10.
3. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102:1083-95.
4. Reulen RC, Frobisher C, Winter DL, Kelly J, Lancashire ER, Stiller CA, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011;305:2311-9.
5. Olsen JH, Moller T, Anderson H, Langmark F, Sankila R, Tryggvadottir L, et al. Lifelong cancer incidence in 47,697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 2009; 101:806-13.
6. de Vathaire F, Francois P, Hill C, Schweisguth O, Rodary C, Sarrazin D, et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 1989; 59:792-6.
7. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010;174: 840-50.
8. Armstrong GT, Liu W, Leisenring W, Yasui Y, Hammond S, Bhatia S, et al. Occurrence of multiple subsequent neoplasms in long-term survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2011;29:3056-64.
9. Friedman DL, Kadan-Lottick NS, Whitton J, Mertens AC, Yasui Y, Liu Y, et al. Increased risk of cancer among siblings of long-term childhood cancer survivors: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2005;14:1922-7.
10. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst 1987;79: 1213-20.
11. Nordfjall K, Svenson U, Norrback KF, Adolfsson R, Roos G. Largescale parent-child comparison confirms a strong paternal influence on telomere length. Eur J Hum Genet 2010;18:385-9.
12. Raynaud CM, Sabatier L, Philipot O, Olaussen KA, Soria JC. Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Crit Rev Oncol Hematol 2008; 66:99-117.
13. Artandi SE, Attardi LD. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 2005;331:881-90.
14. Shay J, Wright W, Werbin H. Loss of telomeric DNA during aging may predispose cells to cancer (review). Int J Oncol 1993;3:559-63.
15. Wentzensen IM, Mirabello L, Pfeiffer RM, Savage SA. The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011;20:1238-50.
16. Ma H, Zhou Z, Wei S, Liu Z, Pooley KA, Dunning AM, et al. Shortened telomere length is associated with increased risk of cancer: a metaanalysis. PLoS ONE 2011;6:e20466.
17. Willeit P, Willeit J, Mayr A, Weger S, Oberhollenzer F, Brandstatter A, et al. Telomere length and risk of incident cancer and cancer mortality. JAMA 2010;304:69-75.
18. Li P, Hou M, Lou F, Bjorkholm M, Xu D. Telomere dysfunction induced by chemotherapeutic agents and radiation in normal human cells. Int J Biochem Cell Biol 2012;44:1531-40.
19. Fumagalli M, Rossiello F, Clerici M, Barozzi S, Cittaro D, Kaplunov JM, et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol 2012;14:355-65.
20. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The childhood cancer survivor study: A national cancer institute-supported resource for outcome and intervention research. J Clin Oncol 2009;27:2308-18.
21. Gadalla SM, Cawthon R, Giri N, Alter BP, Savage SA. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging 2010;2:867-74.
22. Sakoff JA, De Waal E, Garg MB, Denham J, Scorgie FE, Enno A, et al. Telomere length in haemopoietic stem cells can be determined from that of mononuclear blood cells or whole blood. Leuk Lymphoma 2002;43:2017-20.
23. Ness KK, Li C, Mitby PA, Radloff GA, Mertens AC, Davies SM, et al. Characteristics of responders to a request for a buccal cell specimen among survivors of childhood cancer and their siblings. Pediatr Blood Cancer 2010;55:165-70.
24. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002;30:e47.
25. Aviv A, Hunt SC, Lin J, Cao X, Kimura M, Blackburn E. Impartial comparative analysis of measurement of leukocyte telomere length/ DNA content by Southern blots andqPCR. Nucleic Acids Res 2011;39: e134.
26. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-60.
27. Efron B, Tibshirani R. An introduction to the bootstrap. 1st ed. Boca Raton, FL: Chapman and Hall/CRC; 1994.
28. Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010;174:741-52.
29. Hawkins MM, Wilson LM, Burton HS, Potok MH, Winter DL, Marsden HB, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst 1996;88:270-8.
30. Taylor AJ, Croft AP, Palace AM, Winter DL, Reulen RC, Stiller CA, et al. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study. Int J Cancer 2009;125: 2400-5.
31. Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009;27:3901-7.
32. Veiga LH, Bhatti P, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, et al. Chemotherapy and thyroid cancer risk: a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2012;21:92-101.
33. Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2007;99: 300-8.
34. Schroder CP, Wisman GB, de Jong S, van der Graaf WT, Ruiters MH, Mulder NH, et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer 2001;84:1348-53.
35. Beeharry N, Broccoli D. Telomere dynamics in response to chemotherapy. Curr Mol Med 2005;5:187-96.
36. Ilyenko I, Lyaskivska O, Bazyka D. Analysis of relative telomere length and apoptosis in humans exposed to ionising radiation. Exp Oncol 2011;33:235-8.
37. M'Kacher R, Bennaceur-Griscelli A, Girinsky T, Koscielny S, Delhommeau F, Dossou J, et al. Telomere shortening and associated chromosomal instability in peripheral blood lymphocytes of patients with Hodgkin's lymphoma prior to any treatment are predictive of second cancers. Int J Radiat Oncol Biol Phys 2007;68:465-71.
38. Capezzone M, Cantara S, Marchisotta S, Busonero G, Formichi C, Benigni M, et al. Telomere length in neoplastic and nonneoplastic tissues of patients with familial and sporadic papillary thyroid cancer. J Clin Endocrinol Metab 2011;96:E1852-6.
39. He M, Bian B, Gesuwan K, Gulati N, Zhang L, Nilubol N, et al. Telomere length is shorter in affected members of families with familial nonmedullary thyroid cancer. Thyroid 2012.
40. Cantara S, Pisu M, Frau DV, Caria P, Dettori T, Capezzone M, et al. Telomere abnormalities and chromosome fragility in patients affected by familial papillary thyroid cancer. J Clin Endocrinol Metab 2012;97: E1327-31.
41. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ. A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18: 1152-6.
42. Pooley KA, Sandhu MS, Tyrer J, Shah M, Driver KE, Luben RN, et al. Telomere length in prospective and retrospective cancer case-control studies. Cancer Res 2010;70:3170-6.
43. Xie H,WuX,Wang S, Chang D, Pollock RE, Lev D, et al. Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma. Cancer 2013;119:1885-91.
44. Mirabello L, Richards EG, Duong LM, Yu K, Wang Z, Cawthon R, et al. Telomere length and variation in telomere biology genes in individuals with osteosarcoma. Int J Mol Epidemiol Genet 2011;2:19-29.
45. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003;145:1-30.
46. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet 2005;366:662-4.
47. Chakraborty S, Sun CL, Francisco L, Sabado M, Li L, Chang KL, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009; 27:791-8.
48. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell 2001;107:67-77.
49. Hudson MM, Mulrooney DA, Bowers DC, Sklar CA, Green DM, Donaldson SS, et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol 2009;27:2405-14.
50. Dinu I, Liu Y, Leisenring W, Mertens AC, Neglia JP, Hammond S, et al. Prediction of second malignant neoplasm incidence in a large cohort of long-term survivors of childhood cancers. Pediatr Blood Cancer 2008; 50:1026-31.